Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Alexion Pharmaceuticals Inc.
Headquarters: Boston, MA, United States of America
Website: N/A
Year Founded: 1992
Status: Acquired
BioCentury | Oct 29, 2024
Deals
Novartis adds another degrader, this time from Monte Rosa
Deals report: AbbVie acquires Aliada, Roche returns tau mAb to UCB, Monopar licenses AZ’s Wilson disease program, and more
BioCentury | Jun 25, 2024
Product Development
Alnylam: ‘Big win’ amyloidosis readout sets up Amvuttra as standard of care
After endpoint was changed, hotly anticipated HELIOS-B readout meets primary, secondaries as monotherapy, combination
BioCentury | Jun 21, 2024
Management Tracks
ITM names Cavey CEO, plus PureTech, Brainstorm and more
Plus: New chairs for PureTech, Evexta and updates from PharmaEssentia, Brainstorm, Danaher and more
BioCentury | Jan 26, 2024
Finance
Parlaying its biotech brand, J.P. Morgan building venture business
New investment strategy, anchored by bank and led by Stephen Squinto, targets 20-25 deals, including company creation
BioCentury | Nov 29, 2023
Management Tracks
Camille Bedrosian named Amylyx CMO
Plus: Cameron Turtle becomes CEO of Spyre, and updates from Ocuphire and Astraveus
BioCentury | Nov 9, 2023
Regulation
Nov. 8 Quick Takes: FDA approves Lilly’s tirzepatide for weight loss
Plus: Takeda’s fruquintinib approved for colorectal cancer, and updates from Forward, Ascidian, Xencor, UltraDx and more
BioCentury | Oct 25, 2023
Deals
Oct. 24 Quick Takes: BMS buying back Asia rights to mavacamten from LianBio
Plus: Rampart raises $85M series A for DNA-based therapies and updates from Servier, Novartis, Cargo and more
BioCentury | Sep 20, 2023
Data Byte
Immunology companies acquired by pharmas in 2020-23
At least 13 immunology-focused biotechs have been acquired for ≥$1B since start of 2020, with three of the deals announced this year
BioCentury | Sep 20, 2023
Management Tracks
Orwin succeeds Topper as AnaptysBio’s chair
Plus: CDMOs Catalent and Rentschler announce executive changes, and updates from Parexel, Santander, CorriXR and more
BioCentury | Sep 1, 2023
Management Tracks
Huguet to succeed Mayer at Ipsen
Plus: Junshi COO Hui departing, Kaufmann named CSO at Hansa
Items per page:
1 - 10 of 904